The Concept of Divergent Targeting through the Activation and Inhibition of Receptors as a Novel Chemotherapeutic Strategy: Signaling Responses to Strong DNA-Reactive Combinatorial Mimicries

<table>Upregulation of ERCC1 expression in U87MG (a), U87/EGFR (b), and U87/EGFRvIII (c) glioma cells. Cells were treated with the indicated concentrations of Iressa, mechlorethamine (HN2), Iressa + HN2, ZRBA4, or ZR2003, alone or in combination with octreotide (OCT) for 48 h. Cell lysates (40 <i>μ</i>g) were fractionated by SDS-PAGE and probed with anti-ERCC1 (1 : 1000) antibodies (see Materials and Methods for details). Blots were subsequently stripped and reprobed for <i>α</i>-actinin (1 : 1500). Major protein bands of 36 (ERCC1) and 100 kDa (<i>α</i>-actinin) were obtained.</table>

Journal of Signal Transduction

fig6

Figure 6

Figure 6: The Concept of Divergent Targeting through the Activation and Inhibition of Receptors as a Novel Chemotherapeutic Strategy: Signaling Responses to Strong DNA-Reactive Combinatorial Mimicries 

Figure 6 | The Concept of Divergent Targeting through the Activation and Inhibition of Receptors as a Novel Chemotherapeutic Strategy: Signaling Responses to Strong DNA-Reactive Combinatorial Mimicries 